Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BIOMERICA INCBMRA · Entity 8171 | Director | December 13, 2023 | December 14, 2023 |
| NEOGENOMICS INCNEO · Entity 2096 | Director | June 01, 2026 | June 03, 2026 |
| ORASURE TECHNOLOGIES INCOSUR · Entity 6152 | Director | September 06, 2026 | September 09, 2026 |
| Quantum-Si IncQSI · Entity 6440 | Director | May 18, 2026 | May 20, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BIOMERICA INC
Report date December 13, 2023 · Filed December 14, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Non-qualified stock optionSEC Table II · derivative / convertible security · Conversion / exercise price $1.01 · Expires 2034-12-13 | Direct | 75,000 |
Reported balance
After 2023-12-13 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-12-13 · Grant · Acquired 75,000 · Balance 75,000 F1: Options granted to Ms. Coste as part of her Fiscal 2024 Board compensation package. F2: Not Applicable |
| Common stockSEC Table I · non-derivative | Direct | 0 |
Reported balance
Holding disclosure · report date 2023-12-13 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 0 |
Filing footnotes · ownership attribution and instrument terms
F1: Options granted to Ms. Coste as part of her Fiscal 2024 Board compensation package.
F2: Not Applicable
NEOGENOMICS INC
Report date June 01, 2026 · Filed June 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 5,893 |
Reported balance
After 2026-06-01 transaction · row 1
1 source rowRow 1 · 2026-06-01 · Exercise / conversion · Acquired 5,893 · Balance 5,893 F1: Reflects release of restricted stock units that were previously reported on a Form 4. |
| Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2026-06-01 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-01 · Exercise / conversion · Disposed 5,893 · Balance 0 F2: Once vested, the shares of common stock are not subject to expiration. |
| Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 15,970 |
Reported balance
After 2026-06-01 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-06-01 · Grant · Acquired 15,970 · Balance 15,970 F2: Once vested, the shares of common stock are not subject to expiration. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.52 · Expires 2036-06-01 | Direct | 11,069 |
Reported balance
After 2026-06-01 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-06-01 · Grant · Acquired 11,069 · Balance 11,069 |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.76 · Expires 2036-01-01 | Direct | 4,171 |
Reported balance
Holding disclosure · report date 2026-06-01 · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · Balance 4,171 |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects release of restricted stock units that were previously reported on a Form 4.
F2: Once vested, the shares of common stock are not subject to expiration.
ORASURE TECHNOLOGIES INC
Report date September 06, 2026 · Filed September 09, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 204,598 |
Reported balance
After 2026-09-06 transaction · row 1
1 source rowRow 1 · 2026-09-06 · Tax withholding · Disposed 5,116 · Balance 204,598 F1: Withholding of shares to pay the tax liability associated with vesting of restricted shares. |
Filing footnotes · ownership attribution and instrument terms
F1: Withholding of shares to pay the tax liability associated with vesting of restricted shares.
Quantum-Si Inc
Report date May 18, 2026 · Filed May 20, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.85 · Expires 2036-05-18 | Direct | 251,185 |
Reported balance
After 2026-05-18 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-05-18 · Grant · Acquired 251,185 · Balance 251,185 F1: The shares underlying this option vest on the date of the Issuer's next regular annual stockholders meeting, subject to continued service through the applicable vesting date. |
| Class A Common StockSEC Table I · non-derivative | Direct | 114,285 |
Reported balance
Holding disclosure · report date 2026-05-18 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 114,285 |
Filing footnotes · ownership attribution and instrument terms
F1: The shares underlying this option vest on the date of the Issuer's next regular annual stockholders meeting, subject to continued service through the applicable vesting date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
MERIDIAN BIOSCIENCE INC
Report date January 31, 2023 · Filed January 31, 2023
Section 16 reporting ended · disclosed 2023-01-31. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2023-01-31 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2023-01-31 · Grant · Acquired 47,060 · Balance 267,651 F1: Represents 47,060 shares of the Issuer's common stock awarded to the Reporting Person upon the vesting of a portion of an award of performance stock units ("PSUs") in connection with the closing of the transactions contemplated by the Merger Agreement (as defined below). Row 2 · 2023-01-31 · Disposition to issuer · Disposed 267,651 · Balance 0 F2: The shares were disposed of pursuant to the Agreement and Plan of Merger dated as of July 7, 2022 (the "Merger Agreement") by and among the Issuer and SD Biosensor, Inc., a corporation with limited liability organized under the laws of the Republic of Korea whereby, immediately prior to the effective time of the merger contemplated therein (the "Effective Time"), all issued and outstanding shares of Issuer common stock were converted into the right to receive $34.00 per share in cash and, when so converted, automatically cancelled. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.10 · Expires 2029-11-05 | Direct | 0 |
Reported balance
After 2023-01-31 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2023-01-31 · Disposition to issuer · Disposed 66,039 · Balance 0 F3: The Stock Option vested in full and was cancelled pursuant to the Merger Agreement in exchange for a cash payment representing the difference between the per share exercise price of the option and the $34.00 per share merger consideration, less all applicable deductions and withholdings required to be withheld in respect of such payment. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $18.48 · Expires 2030-11-05 | Direct | 0 |
Reported balance
After 2023-01-31 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2023-01-31 · Disposition to issuer · Disposed 83,535 · Balance 0 F4: The Stock Option vested in full and was cancelled pursuant to the Merger Agreement in exchange for a cash payment representing the difference between the per share exercise price of the option and the $34.00 per share merger consideration, less all applicable deductions and withholdings required to be withheld in respect of such payment. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $18.88 · Expires 2031-11-04 | Direct | 0 |
Reported balance
After 2023-01-31 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2023-01-31 · Disposition to issuer · Disposed 82,940 · Balance 0 F5: The Stock Option vested in full and was cancelled pursuant to the Merger Agreement in exchange for a cash payment representing the difference between the per share exercise price of the option and the $34.00 per share merger consideration, less all applicable deductions and withholdings required to be withheld in respect of such payment. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents 47,060 shares of the Issuer's common stock awarded to the Reporting Person upon the vesting of a portion of an award of performance stock units ("PSUs") in connection with the closing of the transactions contemplated by the Merger Agreement (as defined below).
F2: The shares were disposed of pursuant to the Agreement and Plan of Merger dated as of July 7, 2022 (the "Merger Agreement") by and among the Issuer and SD Biosensor, Inc., a corporation with limited liability organized under the laws of the Republic of Korea whereby, immediately prior to the effective time of the merger contemplated therein (the "Effective Time"), all issued and outstanding shares of Issuer common stock were converted into the right to receive $34.00 per share in cash and, when so converted, automatically cancelled.
F3: The Stock Option vested in full and was cancelled pursuant to the Merger Agreement in exchange for a cash payment representing the difference between the per share exercise price of the option and the $34.00 per share merger consideration, less all applicable deductions and withholdings required to be withheld in respect of such payment.
F4: The Stock Option vested in full and was cancelled pursuant to the Merger Agreement in exchange for a cash payment representing the difference between the per share exercise price of the option and the $34.00 per share merger consideration, less all applicable deductions and withholdings required to be withheld in respect of such payment.
F5: The Stock Option vested in full and was cancelled pursuant to the Merger Agreement in exchange for a cash payment representing the difference between the per share exercise price of the option and the $34.00 per share merger consideration, less all applicable deductions and withholdings required to be withheld in respect of such payment.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 06, 2026 Filed Sep 9, 2026 20:12 UTC | ORASURE TECHNOLOGIES INC OSUR · Entity 6152 | Tax withholdingCommon Stock | 5,116 | $3.43 | $17,535.09 |
DisclosureSEC source: 0001470831-26-000880 · form4.xml · nonDerivative · entry 1 Kenny John P. · CIK 0001719325 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 204,598 F1 · shares: Withholding of shares to pay the tax liability associated with vesting of restricted shares. Read SEC document |
| June 03, 2026 Filed Jun 5, 2026 20:01 UTC | ORASURE TECHNOLOGIES INC OSUR · Entity 6152 | GrantCommon Stock | 46,106 | $0.00 | $0.00 |
DisclosureSEC source: 0001470831-26-000517 · form4.xml · nonDerivative · entry 1 Kenny John P. · CIK 0001719325 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 209,714 F1 · kind: Grant of restricted shares under the OraSure Technologies, Inc. Stock Award Plan, which shall vest in full upon the earlier of (i) June 3, 2027, or (ii) immediately prior to the commencement of the Company's 2027 Annual Meeting of Stockholders. Vesting shall cease immediately if the named individual voluntarily ceases to serve as a member of the Board of Directors. Read SEC document |
| June 01, 2026 Filed Jun 3, 2026 23:48 UTC | NEOGENOMICS INC NEO · Entity 2096 | GrantRestricted Stock Unit · Derivative | 15,970 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-040581 · wk-form4_1780530479.xml · derivative · entry 4 Kenny John P. · CIK 0001719325 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,970 Underlying: Common Stock · 15,970 shares Expires not disclosed F2 · derivative.expiration_date: Once vested, the shares of common stock are not subject to expiration. Read SEC document |
| June 01, 2026 Filed Jun 3, 2026 23:48 UTC | NEOGENOMICS INC NEO · Entity 2096 | GrantStock Option (Right to Buy) · Derivative | 11,069 | $0.00 Strike: $10.52 | $0.00 |
DisclosureSEC source: 0001628280-26-040581 · wk-form4_1780530479.xml · derivative · entry 3 Kenny John P. · CIK 0001719325 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,069 Underlying: Common Stock · 11,069 shares Expires 2036-06-01 Read SEC document |
| June 01, 2026 Filed Jun 3, 2026 23:48 UTC | NEOGENOMICS INC NEO · Entity 2096 | Exercise / conversionRestricted Stock Unit · Derivative | 5,893 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-040581 · wk-form4_1780530479.xml · derivative · entry 2 Kenny John P. · CIK 0001719325 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,893 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.expiration_date: Once vested, the shares of common stock are not subject to expiration. Read SEC document |
| June 01, 2026 Filed Jun 3, 2026 23:48 UTC | NEOGENOMICS INC NEO · Entity 2096 | Exercise / conversionCommon Stock | 5,893 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-040581 · wk-form4_1780530479.xml · nonDerivative · entry 1 Kenny John P. · CIK 0001719325 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,893 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Reflects release of restricted stock units that were previously reported on a Form 4. Read SEC document |
| May 18, 2026 Filed May 20, 2026 20:05 UTC | Quantum-Si Inc QSI · Entity 6440 | GrantStock Option (right to buy) · Derivative | 251,185 | $0.00 Strike: $0.85 | $0.00 |
DisclosureSEC source: 0001140361-26-022243 · form4.xml · derivative · entry 2 Kenny John P. · CIK 0001719325 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 251,185 Underlying: Class A Common Stock · 251,185 shares Expires 2036-05-18 F1 · derivative.exercise_date: The shares underlying this option vest on the date of the Issuer's next regular annual stockholders meeting, subject to continued service through the applicable vesting date. Read SEC document |
| January 01, 2026 Filed Jan 5, 2026 23:15 UTC | NEOGENOMICS INC NEO · Entity 2096 | GrantRestricted Stock Unit · Derivative | 5,893 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-000706 · wk-form4_1767654937.xml · derivative · entry 2 Kenny John P. · CIK 0001719325 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,893 Underlying: Common Stock · 5,893 shares Expires not disclosed F1 · derivative.expiration_date: Once vested, the shares of common stock are not subject to expiration. Read SEC document |
| January 01, 2026 Filed Jan 5, 2026 23:15 UTC | NEOGENOMICS INC NEO · Entity 2096 | GrantStock Option (Right to Buy) · Derivative | 4,171 | $0.00 Strike: $11.76 | $0.00 |
DisclosureSEC source: 0001628280-26-000706 · wk-form4_1767654937.xml · derivative · entry 1 Kenny John P. · CIK 0001719325 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,171 Underlying: Common Stock · 4,171 shares Expires 2036-01-01 Read SEC document |
| December 17, 2025 Filed Dec 19, 2025 21:08 UTC | ORASURE TECHNOLOGIES INC OSUR · Entity 6152 | GrantCommon Stock | 10,286 | $2.46 | $25,303.56 |
DisclosureSEC source: 0001470831-25-000448 · form4.xml · nonDerivative · entry 1 Kenny John P. · CIK 0001719325 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 163,608 F1 · shares: Grant of restricted shares under the OraSure Technologies, Inc. Stock Award Plan in lieu of cash fees with immediate vesting. Read SEC document |
| September 24, 2025 Filed Sep 26, 2025 20:26 UTC | ORASURE TECHNOLOGIES INC OSUR · Entity 6152 | GrantCommon Stock | 6,118 | $3.27 | $19,999.74 |
DisclosureSEC source: 0001470831-25-000232 · form4.xml · nonDerivative · entry 1 Kenny John P. · CIK 0001719325 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 153,322 F1 · shares: Grant of restricted shares under the OraSure Technologies, Inc. Stock Award Plan in lieu of cash fees with immediate vesting. Read SEC document |
| June 24, 2025 Filed Jun 25, 2025 20:09 UTC | ORASURE TECHNOLOGIES INC OSUR · Entity 6152 | GrantCommon Stock | 6,657 | $3.01 | $20,025.59 |
DisclosureSEC source: 0001062993-25-012140 · form4.xml · nonDerivative · entry 1 Kenny John P. · CIK 0001719325 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 147,204 F1 · shares: Grant of restricted shares under the OraSure Technologies, Inc. Stock Award Plan in lieu of cash fees with immediate vesting. Read SEC document |
| May 19, 2025 Filed May 21, 2025 20:01 UTC | Quantum-Si Inc QSI · Entity 6440 | GrantStock Option (right to buy) · Derivative | 126,095 | $0.00 Strike: $1.41 | $0.00 |
DisclosureSEC source: 0001140361-25-020048 · form4.xml · derivative · entry 2 Kenny John P. · CIK 0001719325 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 126,095 Underlying: Class A Common Stock · 126,095 shares Expires 2035-05-19 F1 · derivative.exercise_date: The shares underlying this option vest on the date of the Issuer's next regular annual stockholders meeting, subject to continued service through the applicable vesting date. Read SEC document |
| May 14, 2025 Filed May 15, 2025 20:46 UTC | ORASURE TECHNOLOGIES INC OSUR · Entity 6152 | GrantCommon Stock | 71,017 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-25-009567 · form4.xml · nonDerivative · entry 1 Kenny John P. · CIK 0001719325 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 140,547 F1 · kind: Grant of restricted shares under the OraSure Technologies, Inc. Stock Award Plan, which shall vest in full upon the earlier of (i) May 14, 2026, or (ii) immediately prior to the commencement of the Company's 2026 Annual Meeting of Stockholders. Vesting shall cease immediately if the named individual voluntarily ceases to serve as a member of the Board of Directors. Read SEC document |
| March 25, 2025 Filed Mar 27, 2025 20:01 UTC | ORASURE TECHNOLOGIES INC OSUR · Entity 6152 | Tax withholdingCommon Stock | 1,385 | $3.55 | $4,920.21 |
DisclosureSEC source: 0001062993-25-006390 · form4.xml · nonDerivative · entry 1 Kenny John P. · CIK 0001719325 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 69,530 F1 · shares: Withholding of shares to pay the tax liability associated with vesting of restricted shares. Read SEC document |
| February 27, 2025 Filed Feb 28, 2025 02:14 UTC | ORASURE TECHNOLOGIES INC OSUR · Entity 6152 | PurchaseCommon Stock | 47,659 | $3.17 | $151,217.24 |
DisclosureSEC source: 0001062993-25-003842 · form4.xml · nonDerivative · entry 1 Kenny John P. · CIK 0001719325 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 70,915 F1 · kind: Represents shares of common stock purchased in the open market on February 27, 2025. F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.08 to $3.21, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| September 06, 2024 Filed Sep 10, 2024 20:31 UTC | ORASURE TECHNOLOGIES INC OSUR · Entity 6152 | GrantCommon Stock | 23,256 | $4.30 | $100,000.80 |
DisclosureSEC source: 0001062993-24-016411 · form4.xml · nonDerivative · entry 1 Kenny John P. · CIK 0001719325 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,256 F1 · kind: Grant of restricted shares under the OraSure Technologies, Inc. Stock Award Plan, cliff vesting on September 6, 2026. Vesting shall cease immediately if the named individual voluntarily ceases to serve as a member of the Board of Directors. Read SEC document |
| May 16, 2024 Filed May 17, 2024 20:46 UTC | Quantum-Si Inc QSI · Entity 6440 | GrantStock Option (right to buy) · Derivative | 113,281 | $0.00 Strike: $1.86 | $0.00 |
DisclosureSEC source: 0001140361-24-026707 · form4.xml · derivative · entry 1 Kenny John P. · CIK 0001719325 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 113,281 Underlying: Class A Common Stock · 113,281 shares Expires 2034-05-16 F1 · derivative.exercise_date: The shares underlying this option vest on the date of the Issuer's next regular annual stockholders meeting, subject to Mr. Kenny's continued service through the applicable vesting date. Read SEC document |
| December 13, 2023 Filed Dec 14, 2023 22:10 UTC | BIOMERICA INC BMRA · Entity 8171 | GrantNon-qualified stock option · Derivative | 75,000 | Not disclosed Strike: $1.01 | Not disclosed |
DisclosureSEC source: 0001493152-23-044909 · ownership.xml · derivative · entry 2 Kenny John P. · CIK 0001719325 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2034-12-13 F1 · shares: Options granted to Ms. Coste as part of her Fiscal 2024 Board compensation package. F2 · price: Not Applicable Read SEC document |
| August 29, 2023 Filed Dec 11, 2023 22:21 UTC | BIOMERICA INC BMRA · Entity 8171 | GrantNon-qualified stock option · Derivative | 30,000 | Not disclosed Strike: $1.25 | Not disclosed |
DisclosureSEC source: 0001493152-23-044438 · ownership.xml · derivative · entry 2 Kenny John P. · CIK 0001719325 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2033-08-29 F1 · shares: Options granted to Mr. Kenny in August 2023 as a new Board member. Final issuance of the options was subject to and conditioned upon the approval by stockholders of the 2023 Stock Incentive Plan, which occured on December 7, 2023. F3 · price: Not Applicable F2 · derivative.exercise_date: 25% vesting on 12/7/2023, 25% on 12/07/2024, 25% on 12/07/2025 and 25% on 12/07/2026 Read SEC document |
| May 22, 2023 Filed May 24, 2023 20:18 UTC | Quantum-Si Inc QSI · Entity 6440 | GrantClass A Common Stock | 114,285 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-23-026411 · form4.xml · nonDerivative · entry 1 Kenny John P. · CIK 0001719325 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 114,285 F1 · shares: Consists of restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock upon vesting. The RSUs vest in equal annual installments over three years beginning on May 22, 2024, subject to Mr. Kenny's continued service through the applicable vesting date. Read SEC document |
| January 31, 2023 Filed Jan 31, 2023 14:12 UTC | MERIDIAN BIOSCIENCE INC VIVO · Entity 117499 | Disposition to issuerStock Option (Right to Buy) · Derivative | 82,940 | $15.12 Strike: $18.88 | $1,254,052.80 |
DisclosureSEC source: 0001567619-23-001530 · doc1.xml · derivative · entry 5 Kenny John P. · CIK 0001719325 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 82,940 shares Expires 2031-11-04 F5 · price: The Stock Option vested in full and was cancelled pursuant to the Merger Agreement in exchange for a cash payment representing the difference between the per share exercise price of the option and the $34.00 per share merger consideration, less all applicable deductions and withholdings required to be withheld in respect of such payment. F5 · derivative.exercise_date: The Stock Option vested in full and was cancelled pursuant to the Merger Agreement in exchange for a cash payment representing the difference between the per share exercise price of the option and the $34.00 per share merger consideration, less all applicable deductions and withholdings required to be withheld in respect of such payment. F5 · derivative.underlying_shares: The Stock Option vested in full and was cancelled pursuant to the Merger Agreement in exchange for a cash payment representing the difference between the per share exercise price of the option and the $34.00 per share merger consideration, less all applicable deductions and withholdings required to be withheld in respect of such payment. Read SEC document |
| January 31, 2023 Filed Jan 31, 2023 14:12 UTC | MERIDIAN BIOSCIENCE INC VIVO · Entity 117499 | Disposition to issuerStock Option (Right to Buy) · Derivative | 83,535 | $15.52 Strike: $18.48 | $1,296,463.20 |
DisclosureSEC source: 0001567619-23-001530 · doc1.xml · derivative · entry 4 Kenny John P. · CIK 0001719325 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 83,535 shares Expires 2030-11-05 F4 · price: The Stock Option vested in full and was cancelled pursuant to the Merger Agreement in exchange for a cash payment representing the difference between the per share exercise price of the option and the $34.00 per share merger consideration, less all applicable deductions and withholdings required to be withheld in respect of such payment. F4 · derivative.exercise_date: The Stock Option vested in full and was cancelled pursuant to the Merger Agreement in exchange for a cash payment representing the difference between the per share exercise price of the option and the $34.00 per share merger consideration, less all applicable deductions and withholdings required to be withheld in respect of such payment. F4 · derivative.underlying_shares: The Stock Option vested in full and was cancelled pursuant to the Merger Agreement in exchange for a cash payment representing the difference between the per share exercise price of the option and the $34.00 per share merger consideration, less all applicable deductions and withholdings required to be withheld in respect of such payment. Read SEC document |
| January 31, 2023 Filed Jan 31, 2023 14:12 UTC | MERIDIAN BIOSCIENCE INC VIVO · Entity 117499 | Disposition to issuerStock Option (Right to Buy) · Derivative | 66,039 | $23.90 Strike: $10.10 | $1,578,332.10 |
DisclosureSEC source: 0001567619-23-001530 · doc1.xml · derivative · entry 3 Kenny John P. · CIK 0001719325 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 66,039 shares Expires 2029-11-05 F3 · price: The Stock Option vested in full and was cancelled pursuant to the Merger Agreement in exchange for a cash payment representing the difference between the per share exercise price of the option and the $34.00 per share merger consideration, less all applicable deductions and withholdings required to be withheld in respect of such payment. F3 · derivative.exercise_date: The Stock Option vested in full and was cancelled pursuant to the Merger Agreement in exchange for a cash payment representing the difference between the per share exercise price of the option and the $34.00 per share merger consideration, less all applicable deductions and withholdings required to be withheld in respect of such payment. F3 · derivative.underlying_shares: The Stock Option vested in full and was cancelled pursuant to the Merger Agreement in exchange for a cash payment representing the difference between the per share exercise price of the option and the $34.00 per share merger consideration, less all applicable deductions and withholdings required to be withheld in respect of such payment. Read SEC document |
| January 31, 2023 Filed Jan 31, 2023 14:12 UTC | MERIDIAN BIOSCIENCE INC VIVO · Entity 117499 | Disposition to issuerCommon Stock | 267,651 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001567619-23-001530 · doc1.xml · nonDerivative · entry 2 Kenny John P. · CIK 0001719325 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F2 · price: The shares were disposed of pursuant to the Agreement and Plan of Merger dated as of July 7, 2022 (the "Merger Agreement") by and among the Issuer and SD Biosensor, Inc., a corporation with limited liability organized under the laws of the Republic of Korea whereby, immediately prior to the effective time of the merger contemplated therein (the "Effective Time"), all issued and outstanding shares of Issuer common stock were converted into the right to receive $34.00 per share in cash and, when so converted, automatically cancelled. Read SEC document |
| January 31, 2023 Filed Jan 31, 2023 14:12 UTC | MERIDIAN BIOSCIENCE INC VIVO · Entity 117499 | GrantCommon Stock | 47,060 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001567619-23-001530 · doc1.xml · nonDerivative · entry 1 Kenny John P. · CIK 0001719325 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 267,651 F1 · shares: Represents 47,060 shares of the Issuer's common stock awarded to the Reporting Person upon the vesting of a portion of an award of performance stock units ("PSUs") in connection with the closing of the transactions contemplated by the Merger Agreement (as defined below). F1 · price: Represents 47,060 shares of the Issuer's common stock awarded to the Reporting Person upon the vesting of a portion of an award of performance stock units ("PSUs") in connection with the closing of the transactions contemplated by the Merger Agreement (as defined below). Read SEC document |
| November 04, 2022 Filed Nov 8, 2022 14:25 UTC | MERIDIAN BIOSCIENCE INC VIVO · Entity 117499 | Tax withholdingCommon Stock | 4,271 | $32.01 | $136,714.71 |
DisclosureSEC source: 0001127602-22-025087 · form4.xml · nonDerivative · entry 1 Kenny John P. · CIK 0001719325 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 220,591 F1 · shares: Represent restricted stock units withheld by the Company under the net share settlement method to cover certain taxes due upon vesting of units granted on November 4, 2021. Read SEC document |
| October 03, 2022 Filed Oct 5, 2022 15:54 UTC | MERIDIAN BIOSCIENCE INC VIVO · Entity 117499 | Tax withholdingCommon Stock | 40,269 | $31.53 | $1,269,681.57 |
DisclosureSEC source: 0001127602-22-023690 · form4.xml · nonDerivative · entry 1 Kenny John P. · CIK 0001719325 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 224,862 F1 · shares: Represent restricted stock units withheld by the Company under the net share settlement method to cover certain taxes due upon vesting of units granted on November 15, 2021. Read SEC document |
| June 27, 2022 Filed Jun 28, 2022 09:42 UTC | MERIDIAN BIOSCIENCE INC VIVO · Entity 117499 | Exercise / conversionStock Options (Right to Buy) · Derivative | 61,437 | $0.00 Strike: $10.10 | $0.00 |
DisclosureSEC source: 0001127602-22-018184 · form4.xml · derivative · entry 6 Kenny John P. · CIK 0001719325 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,039 Underlying: Common Stock · 61,437 shares Expires 2029-11-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · kind: The option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person effective November 15, 2021. F6 · derivative.exercise_date: These non-qualified options were awarded under the 2012 Stock Incentive Plan pursuant to Mr. Kenny's Amended and Restated Employment Agreement effective October 1, 2019. The options vest on a pro rata basis over the three (3) years from the Agreement's effective date. Read SEC document |
| June 27, 2022 Filed Jun 28, 2022 09:42 UTC | MERIDIAN BIOSCIENCE INC VIVO · Entity 117499 | SaleCommon Stock | 61,437 | $30.39 | $1,866,787.82 |
DisclosureSEC source: 0001127602-22-018184 · form4.xml · nonDerivative · entry 4 Kenny John P. · CIK 0001719325 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 265,131 F3 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person effective November 15, 2021. F4 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $30.00 to $30.76. The Reporting Person undertakes to provide full pricing information if requested by the Securities and Exchange Commission, the issuer or a security holder of the issuer. Read SEC document |
| June 27, 2022 Filed Jun 28, 2022 09:42 UTC | MERIDIAN BIOSCIENCE INC VIVO · Entity 117499 | Exercise / conversionCommon Stock | 61,437 | $10.10 | $620,513.70 |
DisclosureSEC source: 0001127602-22-018184 · form4.xml · nonDerivative · entry 3 Kenny John P. · CIK 0001719325 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 326,568 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 24, 2022 Filed Jun 28, 2022 09:42 UTC | MERIDIAN BIOSCIENCE INC VIVO · Entity 117499 | Exercise / conversionStock Options (Right to Buy) · Derivative | 13,559 | $0.00 Strike: $10.10 | $0.00 |
DisclosureSEC source: 0001127602-22-018184 · form4.xml · derivative · entry 5 Kenny John P. · CIK 0001719325 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 127,476 Underlying: Common Stock · 13,559 shares Expires 2029-11-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · kind: The option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person effective November 15, 2021. F6 · derivative.exercise_date: These non-qualified options were awarded under the 2012 Stock Incentive Plan pursuant to Mr. Kenny's Amended and Restated Employment Agreement effective October 1, 2019. The options vest on a pro rata basis over the three (3) years from the Agreement's effective date. Read SEC document |
| June 24, 2022 Filed Jun 28, 2022 09:42 UTC | MERIDIAN BIOSCIENCE INC VIVO · Entity 117499 | SaleCommon Stock | 13,559 | $30.00 | $406,836.44 |
DisclosureSEC source: 0001127602-22-018184 · form4.xml · nonDerivative · entry 2 Kenny John P. · CIK 0001719325 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 265,131 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person effective November 15, 2021. F2 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $30.00 to $30.11. The Reporting Person undertakes to provide full pricing information if requested by the Securities and Exchange Commission, the issuer or a security holder of the issuer. Read SEC document |
| June 24, 2022 Filed Jun 28, 2022 09:42 UTC | MERIDIAN BIOSCIENCE INC VIVO · Entity 117499 | Exercise / conversionCommon Stock | 13,559 | $10.10 | $136,945.90 |
DisclosureSEC source: 0001127602-22-018184 · form4.xml · nonDerivative · entry 1 Kenny John P. · CIK 0001719325 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 278,690 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 23, 2022 Filed Jun 24, 2022 12:33 UTC | MERIDIAN BIOSCIENCE INC VIVO · Entity 117499 | Exercise / conversionStock Options (Right to Buy) · Derivative | 14,607 | $0.00 Strike: $10.10 | $0.00 |
DisclosureSEC source: 0001127602-22-018097 · form4.xml · derivative · entry 8 Kenny John P. · CIK 0001719325 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 141,035 Underlying: Common Stock · 14,607 shares Expires 2029-11-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · kind: The option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person effective November 15, 2021. F9 · derivative.exercise_date: These non-qualified options were awarded under the 2012 Stock Incentive Plan pursuant to Mr. Kenny's Amended and Restated Employment Agreement effective October 1, 2019. The options vest on a pro rata basis over the three (3) years from the Agreement's effective date. Read SEC document |
| June 23, 2022 Filed Jun 24, 2022 12:33 UTC | MERIDIAN BIOSCIENCE INC VIVO · Entity 117499 | Exercise / conversionStock Options (Right to Buy) · Derivative | 5,349 | $0.00 Strike: $14.50 | $0.00 |
DisclosureSEC source: 0001127602-22-018097 · form4.xml · derivative · entry 7 Kenny John P. · CIK 0001719325 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,349 shares Expires 2027-10-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · kind: The option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person effective November 15, 2021. F6 · derivative.exercise_date: These non-qualified options were awarded under the 2012 Stock Incentive Plan upon Mr. Kenny being hired as Chief Executive Officer. The options vested in four (4) equal installments from the date of grant until fully vested on October 9, 2021. Read SEC document |
| June 23, 2022 Filed Jun 24, 2022 12:33 UTC | MERIDIAN BIOSCIENCE INC VIVO · Entity 117499 | SaleCommon Stock | 19,956 | $29.98 | $598,209.04 |
DisclosureSEC source: 0001127602-22-018097 · form4.xml · nonDerivative · entry 5 Kenny John P. · CIK 0001719325 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 265,131 F3 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person effective November 15, 2021. F4 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $29.61 to $30.13. The Reporting Person undertakes to provide full pricing information if requested by the Securities and Exchange Commission, the issuer or a security holder of the issuer. Read SEC document |
| June 23, 2022 Filed Jun 24, 2022 12:33 UTC | MERIDIAN BIOSCIENCE INC VIVO · Entity 117499 | Exercise / conversionCommon Stock | 14,607 | $10.10 | $147,530.70 |
DisclosureSEC source: 0001127602-22-018097 · form4.xml · nonDerivative · entry 4 Kenny John P. · CIK 0001719325 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 285,087 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 23, 2022 Filed Jun 24, 2022 12:33 UTC | MERIDIAN BIOSCIENCE INC VIVO · Entity 117499 | Exercise / conversionCommon Stock | 5,349 | $14.50 | $77,560.50 |
DisclosureSEC source: 0001127602-22-018097 · form4.xml · nonDerivative · entry 3 Kenny John P. · CIK 0001719325 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 270,480 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 22, 2022 Filed Jun 24, 2022 12:33 UTC | MERIDIAN BIOSCIENCE INC VIVO · Entity 117499 | Exercise / conversionStock Options (Right to Buy) · Derivative | 44,651 | $0.00 Strike: $14.50 | $0.00 |
DisclosureSEC source: 0001127602-22-018097 · form4.xml · derivative · entry 6 Kenny John P. · CIK 0001719325 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,349 Underlying: Common Stock · 44,651 shares Expires 2027-10-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · kind: The option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person effective November 15, 2021. F6 · derivative.exercise_date: These non-qualified options were awarded under the 2012 Stock Incentive Plan upon Mr. Kenny being hired as Chief Executive Officer. The options vested in four (4) equal installments from the date of grant until fully vested on October 9, 2021. Read SEC document |
| June 22, 2022 Filed Jun 24, 2022 12:33 UTC | MERIDIAN BIOSCIENCE INC VIVO · Entity 117499 | SaleCommon Stock | 44,651 | $29.72 | $1,326,920.56 |
DisclosureSEC source: 0001127602-22-018097 · form4.xml · nonDerivative · entry 2 Kenny John P. · CIK 0001719325 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 265,131 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person effective November 15, 2021. F2 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $29.50 to $29.94. The Reporting Person undertakes to provide full pricing information if requested by the Securities and Exchange Commission, the issuer or a security holder of the issuer. Read SEC document |
| June 22, 2022 Filed Jun 24, 2022 12:33 UTC | MERIDIAN BIOSCIENCE INC VIVO · Entity 117499 | Exercise / conversionCommon Stock | 44,651 | $14.50 | $647,439.50 |
DisclosureSEC source: 0001127602-22-018097 · form4.xml · nonDerivative · entry 1 Kenny John P. · CIK 0001719325 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 309,782 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 15, 2021 Filed Nov 16, 2021 15:56 UTC | MERIDIAN BIOSCIENCE INC VIVO · Entity 117499 | GrantCommon Stock | 155,511 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-21-029297 · form4.xml · nonDerivative · entry 2 Kenny John P. · CIK 0001719325 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 265,131 F2 · price: Restricted share units granted pursuant to 2021 Omnibus Award Plan scheduled to vest as follows: (i) 99,505 on October 1, 2022; and (ii) 56,006 on November 15, 2023. Read SEC document |
| November 15, 2021 Filed Nov 16, 2021 15:56 UTC | MERIDIAN BIOSCIENCE INC VIVO · Entity 117499 | OtherCommon Stock | 155,511 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-21-029297 · form4.xml · nonDerivative · entry 1 Kenny John P. · CIK 0001719325 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,620 F1 · price: Restricted share units granted pursuant to 2012 Stock Incentive Plan rescinded by the Issuer. Read SEC document |
| November 04, 2021 Filed Nov 8, 2021 16:06 UTC | MERIDIAN BIOSCIENCE INC VIVO · Entity 117499 | GrantStock Options (Right to Buy) · Derivative | 82,940 | $0.00 Strike: $18.88 | $0.00 |
DisclosureSEC source: 0001127602-21-028572 · form4.xml · derivative · entry 2 Kenny John P. · CIK 0001719325 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,940 Underlying: Common Stock · 82,940 shares Expires 2031-11-04 F2 · derivative.exercise_date: These non-qualified options are awarded under the 2021 Omnibus Award Plan and vest as follows: (i) 25% of the options awarded vest on November 4, 2022; and (ii) the remaining 75% of the options awarded vest pro rata each month from November 4, 2022 through November 4, 2025. Read SEC document |
| November 04, 2021 Filed Nov 8, 2021 16:06 UTC | MERIDIAN BIOSCIENCE INC VIVO · Entity 117499 | GrantCommon Stock | 56,472 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-028572 · form4.xml · nonDerivative · entry 1 Kenny John P. · CIK 0001719325 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 265,131 F1 · shares: These restricted stock units are awarded under the 2021 Omnibus Award Plan and vest in four equal installments from the date of grant (i.e., vest 25% per year until fully vested on November 4, 2025). Read SEC document |
| March 17, 2021 Filed Mar 18, 2021 08:37 UTC | MERIDIAN BIOSCIENCE INC VIVO · Entity 117499 | SaleCommon Stock | 30,000 | $25.00 | $750,000.00 |
DisclosureSEC source: 0001127602-21-011258 · form4.xml · nonDerivative · entry 1 Kenny John P. · CIK 0001719325 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 208,659 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person effective November 9, 2020. Read SEC document |
| March 10, 2021 Filed Mar 11, 2021 16:29 UTC | MERIDIAN BIOSCIENCE INC VIVO · Entity 117499 | SaleCommon Stock | 10,000 | $25.00 | $250,000.00 |
DisclosureSEC source: 0001127602-21-010225 · form4.xml · nonDerivative · entry 1 Kenny John P. · CIK 0001719325 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 238,659 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person effective November 9, 2020. Read SEC document |
| February 16, 2021 Filed Feb 17, 2021 10:14 UTC | MERIDIAN BIOSCIENCE INC VIVO · Entity 117499 | Exercise / conversionStock Options (Right to Buy) · Derivative | 2,082 | $0.00 Strike: $10.10 | $0.00 |
DisclosureSEC source: 0001127602-21-006067 · form4.xml · derivative · entry 3 Kenny John P. · CIK 0001719325 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 155,642 Underlying: Common Stock · 2,082 shares Expires 2029-11-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · kind: The option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person effective September 15, 2020. F4 · derivative.exercise_date: These non-qualified options were awarded under the 2012 Stock Incentive Plan pursuant to Mr. Kenny's Amended and Restated Employment Agreement effective October 1, 2019. The options vest on a pro rata basis over the three (3) years from the Agreement's effective date. Read SEC document |
| February 16, 2021 Filed Feb 17, 2021 10:14 UTC | MERIDIAN BIOSCIENCE INC VIVO · Entity 117499 | SaleCommon Stock | 2,359 | $30.35 | $71,603.91 |
DisclosureSEC source: 0001127602-21-006067 · form4.xml · nonDerivative · entry 2 Kenny John P. · CIK 0001719325 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 248,659 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person effective September 15, 2020. F2 · price: Prices range from $30.02 per share to $30.55 per share. The reporting person undertakes to provide full pricing information if requested by the Securities and Exchange Commission, the issuer or a security holder of the issuer. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.